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background:  IMPROVE-IT is a randomized, double-blind trial evaluating whether the addition of ezetimibe (EZE) to simvastatin (simva) 
improves CV outcomes over statin monotherapy in post-ACS patients. The REACH score predicts secondary CV events in outpatients with 
known CV disease (Am J Med 2012;125). We hypothesized that the REACH score will identify a post-ACS population at highest risk for CV 
events in the IMPROVE IT trial and define a subgroup that derives greatest benefit from the addition of EZE to a statin.
methods:  18,144 patients stabilized after ACS were randomized to EZE/simva 10/40mg or simva 40mg. The primary endpoint was the 
composite of CV death, major coronary event (MCE) or stroke. The predictive ability of the baseline REACH score for the primary endpoint 
was assessed in aggregate and will be evaluated by treatment pending final database lock and unblinding in October.
Results:  The median REACH score was 14 (12, 15; Fig 1a). The risk of CV death, MCE or stroke was significantly higher in all quartiles 
compared to Q1 (Q2 HR 1.09, 1.02-1.18; Q3 HR 1.26, 1.15-1.38; Q4 HR 1.63, 1.51-1.75; Fig 1b). By treatment analysis is pending 
unblinding.
conclusion:  his pre-specified preliminary analysis of the IMPROVE-IT trial found that the REACH score, validated in a stable population, 
also predicts long-term CV outcomes in post-ACS patients in a graded fashion. Future analysis will address whether the REACH score 
identifies a subgroup experiencing greatest benefit from the addition of EZE to a statin.
 
